Compare Cytokinetics Inc (CYTK) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Gigacloud Technology Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Gigacloud Technology Inc trades at $57.43 (market cap $2.02B). The key difference: Cytokinetics Inc is far larger — about 4.3× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Gigacloud Technology Inc for 21 Days on average.
| CYTK | GCT | |
|---|---|---|
Market Cap | $8.62B | $2.02B |
Volume | 2,594,626 | 1,020,985 |
Sector | Health | Technology |
52-Week High | $87.26 | $56.42 |
52-Week Low | $54.76 | $25.46 |
Typical Hold Time | 19 Days | 21 Days |
Enterprise Value | $8.72B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
GCT trades at $55.96, up 2.19% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 10.65% net margins, and 27.6% YoY revenue growth in Q2 2026. Recent news highlights institutional interest and European expansion driving optimism.
The outlook remains positive with 66.7% analyst buy ratings and a $32.50 consensus target, though RSI levels suggest potential near-term consolidation. Key risks include insider selling activity and market volatility, but strong cash flow generation and disciplined expansion support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
